Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erdafitinib in advanced solid tumors with FGFR alterations
2023-510301-18-00Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2019
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, open-label trial of erdafitinib in Nonhematologic neoplasms, cholangiocarcinoma (CCA) and primary brain neoplasm (4 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Objective response rate in Broad Panel and Core Panel cohorts and Objective response rate in Pediatric cohort. Started Dec 2019; status: completed.
02
Drugs
erdafitinib
03
Conditions
Nonhematologic neoplasmscholangiocarcinoma (CCA)primary brain neoplasm
Beyond the preview
Go deeper on 2023-510301-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510301-18-00.